|
The inspection was conducted from 27 November 2023 to 01 December 2023 at Mandva, Gujarat, India facility.
At the end of the inspection, the company has received Form 483 with three (3) observations. The company said that there is no data integrity observation.
Alkem Laboratories is engaged in pharmaceutical business with global operations. The company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.
The company’s consolidated net profit surged 87.6% to Rs 620.52 crore on 11.7% jump in net sales to Rs 3,440.17 crore in Q2 FY24 over Q2 FY23.
The scrip declined 1.78% to settle at Rs 4,641.40 on Friday, 1 December 2023.
|